Living evidence in response to controversies about the use of antimalarials in COVID-19
Rev Esp Cardiol (Engl Ed). 2020 Aug;73(8):693-694.
doi: 10.1016/j.rec.2020.05.016.
Epub 2020 May 29.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Cardiología, Hospital Universitario de Burgos, Burgos, Spain. Electronic address: ebevidencia@gmail.com.
- 2 Centro Evidencia UC, Centro Asociado Cochrane Chile, Pontificia Universidad Católica de Chile, Santiago, Chile.
- 3 Centro Evidencia UC, Centro Asociado Cochrane Chile, Pontificia Universidad Católica de Chile, Santiago, Chile; Fundación Epistemonikos, Santiago, Chile.
- 4 Centro Evidencia UC, Centro Asociado Cochrane Chile, Pontificia Universidad Católica de Chile, Santiago, Chile; Fundación Epistemonikos, Santiago, Chile; Departamento de Medicina Interna, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
No abstract available
MeSH terms
-
Antimalarials / adverse effects
-
Antimalarials / therapeutic use*
-
COVID-19
-
Chloroquine / adverse effects
-
Chloroquine / therapeutic use
-
Coronavirus Infections / drug therapy*
-
Humans
-
Hydroxychloroquine / adverse effects
-
Hydroxychloroquine / therapeutic use
-
Pandemics
-
Pneumonia, Viral / drug therapy*
-
Treatment Outcome
Substances
-
Antimalarials
-
Hydroxychloroquine
-
Chloroquine